Transperineal laser ablation as a new minimally invasive surgical therapy for benign prostatic hyperplasia: a systematic review of existing literature
- PMID: 37745187
- PMCID: PMC10515526
- DOI: 10.1177/17562872231198634
Transperineal laser ablation as a new minimally invasive surgical therapy for benign prostatic hyperplasia: a systematic review of existing literature
Abstract
Introduction: Transperineal laser ablation (TPLA) of the prostate is a new, minimally invasive technique for benign prostatic hyperplasia (BPH) with promising effectiveness and safety outcomes. This systematic review aims to provide an update of existing literature.
Methods: A literature review was performed in Pubmed/MEDLINE, Embase, Cochrane Library, and clinicaltrials.gov from January 2000 up to April 2023. Data extraction and risk of bias were performed independently by three authors.
Results: A total of 11 studies were included, among which 9 were observational, 1 randomized controlled trial, 1 animal study, while 2 of them were comparative (1 with prostatic artery embolization and 1 with transurethral resection of the prostate). Functional outcomes were improved in the majority of studies both for objective (maximum flow rate and post-void residual) and subjective outcomes (improvement of International Prostate Symptom Score and quality of life). Complication rates ranged between 1.9% and 2.3% for hematuria, 3.7% and 36.3% for dysuria, 1.9% and 19% for acute urinary retention, 0.6% and 9.1% for orchitis/urinary tract infections, and 0.6% and 4.8% for prostatic abscess formation. Regarding sexual function, >95% of patients retained their ejaculation while erectile function was maintained or improved.
Conclusion: TPLA of the prostate is an innovative, minimally invasive technique for managing patients with BPH. Existing studies indicate an effective technique in reducing International Prostate Symptom Score and quality of life scores, post-void residual reduction, and increase in Qmax, albeit the measured improvements in terms of Qmax are not equal to transurethral resection of the prostate. Although sexual function is maintained, the mean catheterization time is 7 days, and no long-term data are available for most patients.
Keywords: BPH; LUTS; TPLA; laser; laser ablation; prostate.
© The Author(s), 2023.
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures




Similar articles
-
Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.Cochrane Database Syst Rev. 2019 Feb 13;2(2):CD013143. doi: 10.1002/14651858.CD013143.pub2. Cochrane Database Syst Rev. 2019. PMID: 30759311 Free PMC article.
-
Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction.Eur Urol. 2021 Jul;80(1):95-103. doi: 10.1016/j.eururo.2020.08.018. Epub 2020 Aug 28. Eur Urol. 2021. PMID: 32868137
-
Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.Cochrane Database Syst Rev. 2019 May 25;5(5):CD012832. doi: 10.1002/14651858.CD012832.pub2. Cochrane Database Syst Rev. 2019. PMID: 31128077 Free PMC article.
-
Ultrasound-guided transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a new minimally invasive interventional therapy.Acta Radiol. 2022 Apr;63(4):553-558. doi: 10.1177/02841851211003289. Epub 2021 Mar 28. Acta Radiol. 2022. PMID: 33779301
-
Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies.BMJ Open. 2019 Aug 21;9(8):e028855. doi: 10.1136/bmjopen-2018-028855. BMJ Open. 2019. PMID: 31439603 Free PMC article.
Cited by
-
Anatomic and Clinical Effects of Focal Laser Ablation of the Prostate on Symptomatic Benign Prostatic Hyperplasia.Cancers (Basel). 2025 Jan 31;17(3):475. doi: 10.3390/cancers17030475. Cancers (Basel). 2025. PMID: 39941842 Free PMC article.
-
Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study.BJU Int. 2025 Sep;136(3):473-483. doi: 10.1111/bju.16795. Epub 2025 May 28. BJU Int. 2025. PMID: 40432395 Free PMC article. Clinical Trial.
-
Letter to the editor for the article "Transperineal laser ablation (TPLA) of the prostate for benign prostatic obstruction: the first 100 patients cohort of a prospective, single-center study".World J Urol. 2024 Sep 3;42(1):502. doi: 10.1007/s00345-024-05213-9. World J Urol. 2024. PMID: 39225861 No abstract available.
-
Echolaser Focal Treatment for Prostate Cancer Guided by Fiducial Marker Placement.Cancers (Basel). 2025 May 20;17(10):1707. doi: 10.3390/cancers17101707. Cancers (Basel). 2025. PMID: 40427204 Free PMC article.
-
Outcomes and safety of trans perineal laser ablation of the prostate: a systematic review.World J Urol. 2025 Jun 23;43(1):385. doi: 10.1007/s00345-025-05753-8. World J Urol. 2025. PMID: 40548982 Review.
References
-
- Gravas SCJ, Gacci M, Gratzke C, et al.. EAU Guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). In: Paper presented at the EAU annual congress, Amsterdam, 2022. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidel.... accessed 1 May 2023.
-
- Egan KB, Burnett AL, McVary KT, et al.. The co-occurring syndrome-coexisting erectile dysfunction and benign prostatic hyperplasia and their clinical correlates in aging men: results from the national health and nutrition examination survey. Urology 2015; 86: 570–580. - PubMed
-
- Herrmann TRW. Enucleation is enucleation is enucleation is enucleation. World J Urol 2016; 34: 1353–1355. - PubMed
-
- Ahyai SA, Gilling P, Kaplan SA, et al.. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010; 58: 384–397. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous